vs
Designer Brands Inc.（DBI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Designer Brands Inc.的1.0倍（$772.1M vs $752.4M），Revvity净利率更高（12.7% vs 2.4%，领先10.3%），Revvity同比增速更快（5.9% vs -3.2%），Revvity自由现金流更多（$161.8M vs $57.5M），过去两年Revvity的营收复合增速更高（9.0% vs -0.1%）
Designer Brands Inc.是一家美国鞋履及时尚配饰零售商，主打销售设计师品牌与知名品牌商品，旗下拥有知名连锁零售品牌DSW（设计师鞋履仓库），目前在美国经营超过500家线下门店，同时运营线上电商平台。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
DBI vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.0倍
$752.4M
营收增速更快
RVTY
高出9.0%
-3.2%
净利率更高
RVTY
高出10.3%
2.4%
自由现金流更多
RVTY
多$104.3M
$57.5M
两年增速更快
RVTY
近两年复合增速
-0.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $752.4M | $772.1M |
| 净利润 | $18.2M | $98.4M |
| 毛利率 | 45.1% | — |
| 营业利润率 | 5.7% | 14.5% |
| 净利率 | 2.4% | 12.7% |
| 营收同比 | -3.2% | 5.9% |
| 净利润同比 | 40.0% | 3.9% |
| 每股收益（稀释后） | $0.35 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DBIRVTY
| Q4 25 | $752.4M | $772.1M | ||
| Q3 25 | $739.8M | $698.9M | ||
| Q2 25 | $686.9M | $720.3M | ||
| Q1 25 | $713.6M | $664.8M | ||
| Q4 24 | $777.2M | $729.4M | ||
| Q3 24 | $771.9M | $684.0M | ||
| Q2 24 | $746.6M | $691.7M | ||
| Q1 24 | $754.3M | $649.9M |
净利润DBIRVTY
| Q4 25 | $18.2M | $98.4M | ||
| Q3 25 | $10.8M | $46.7M | ||
| Q2 25 | $-17.4M | $53.9M | ||
| Q1 25 | $-38.2M | $42.2M | ||
| Q4 24 | $13.0M | $94.6M | ||
| Q3 24 | $13.8M | $94.4M | ||
| Q2 24 | $783.0K | $55.4M | ||
| Q1 24 | $-29.6M | $26.0M |
毛利率DBIRVTY
| Q4 25 | 45.1% | — | ||
| Q3 25 | 43.7% | 53.6% | ||
| Q2 25 | 43.0% | 54.5% | ||
| Q1 25 | 75.7% | 56.5% | ||
| Q4 24 | 43.0% | — | ||
| Q3 24 | 44.0% | 56.3% | ||
| Q2 24 | 44.2% | 55.7% | ||
| Q1 24 | 38.8% | 54.6% |
营业利润率DBIRVTY
| Q4 25 | 5.7% | 14.5% | ||
| Q3 25 | 3.6% | 11.7% | ||
| Q2 25 | -1.1% | 12.6% | ||
| Q1 25 | -3.6% | 10.9% | ||
| Q4 24 | 2.9% | 16.3% | ||
| Q3 24 | 3.7% | 14.3% | ||
| Q2 24 | 1.3% | 12.4% | ||
| Q1 24 | -4.8% | 6.8% |
净利率DBIRVTY
| Q4 25 | 2.4% | 12.7% | ||
| Q3 25 | 1.5% | 6.7% | ||
| Q2 25 | -2.5% | 7.5% | ||
| Q1 25 | -5.3% | 6.4% | ||
| Q4 24 | 1.7% | 13.0% | ||
| Q3 24 | 1.8% | 13.8% | ||
| Q2 24 | 0.1% | 8.0% | ||
| Q1 24 | -3.9% | 4.0% |
每股收益（稀释后）DBIRVTY
| Q4 25 | $0.35 | $0.86 | ||
| Q3 25 | $0.22 | $0.40 | ||
| Q2 25 | $-0.36 | $0.46 | ||
| Q1 25 | $-0.69 | $0.35 | ||
| Q4 24 | $0.24 | $0.77 | ||
| Q3 24 | $0.24 | $0.77 | ||
| Q2 24 | $0.01 | $0.45 | ||
| Q1 24 | $-899.54 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $51.4M | $919.9M |
| 总债务越低越好 | $463.1M | — |
| 股东权益账面价值 | $298.6M | $7.3B |
| 总资产 | $2.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.55× | — |
8季度趋势，按日历期对齐
现金及短期投资DBIRVTY
| Q4 25 | $51.4M | $919.9M | ||
| Q3 25 | $44.9M | $931.4M | ||
| Q2 25 | $46.0M | $991.8M | ||
| Q1 25 | $44.8M | $1.1B | ||
| Q4 24 | $36.2M | $1.2B | ||
| Q3 24 | $38.8M | $1.2B | ||
| Q2 24 | $43.4M | $2.0B | ||
| Q1 24 | $49.2M | $1.7B |
总债务DBIRVTY
| Q4 25 | $463.1M | — | ||
| Q3 25 | $509.6M | — | ||
| Q2 25 | $516.2M | — | ||
| Q1 25 | $484.3M | — | ||
| Q4 24 | $529.6M | — | ||
| Q3 24 | $459.0M | — | ||
| Q2 24 | $469.3M | — | ||
| Q1 24 | $420.3M | — |
股东权益DBIRVTY
| Q4 25 | $298.6M | $7.3B | ||
| Q3 25 | $280.8M | $7.4B | ||
| Q2 25 | $266.9M | $7.6B | ||
| Q1 25 | $278.5M | $7.6B | ||
| Q4 24 | $318.5M | $7.7B | ||
| Q3 24 | $355.5M | $7.9B | ||
| Q2 24 | $358.5M | $7.9B | ||
| Q1 24 | $359.2M | $7.8B |
总资产DBIRVTY
| Q4 25 | $2.1B | $12.2B | ||
| Q3 25 | $2.1B | $12.1B | ||
| Q2 25 | $2.1B | $12.4B | ||
| Q1 25 | $2.0B | $12.4B | ||
| Q4 24 | $2.1B | $12.4B | ||
| Q3 24 | $2.1B | $12.8B | ||
| Q2 24 | $2.2B | $13.4B | ||
| Q1 24 | $2.1B | $13.4B |
负债/权益比DBIRVTY
| Q4 25 | 1.55× | — | ||
| Q3 25 | 1.81× | — | ||
| Q2 25 | 1.93× | — | ||
| Q1 25 | 1.74× | — | ||
| Q4 24 | 1.66× | — | ||
| Q3 24 | 1.29× | — | ||
| Q2 24 | 1.31× | — | ||
| Q1 24 | 1.17× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $66.5M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $57.5M | $161.8M |
| 自由现金流率自由现金流/营收 | 7.6% | 21.0% |
| 资本支出强度资本支出/营收 | 1.2% | 2.6% |
| 现金转化率经营现金流/净利润 | 3.65× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $99.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流DBIRVTY
| Q4 25 | $66.5M | $182.0M | ||
| Q3 25 | $21.4M | $138.5M | ||
| Q2 25 | $-20.4M | $134.3M | ||
| Q1 25 | $70.1M | $128.2M | ||
| Q4 24 | $-9.8M | $174.2M | ||
| Q3 24 | $41.6M | $147.9M | ||
| Q2 24 | $-19.7M | $158.6M | ||
| Q1 24 | $-40.1M | $147.6M |
自由现金流DBIRVTY
| Q4 25 | $57.5M | $161.8M | ||
| Q3 25 | $11.9M | $120.0M | ||
| Q2 25 | $-27.6M | $115.5M | ||
| Q1 25 | $58.1M | $112.2M | ||
| Q4 24 | $-19.2M | $149.8M | ||
| Q3 24 | $28.0M | $125.6M | ||
| Q2 24 | $-35.6M | $136.6M | ||
| Q1 24 | $-52.8M | $129.7M |
自由现金流率DBIRVTY
| Q4 25 | 7.6% | 21.0% | ||
| Q3 25 | 1.6% | 17.2% | ||
| Q2 25 | -4.0% | 16.0% | ||
| Q1 25 | 8.1% | 16.9% | ||
| Q4 24 | -2.5% | 20.5% | ||
| Q3 24 | 3.6% | 18.4% | ||
| Q2 24 | -4.8% | 19.7% | ||
| Q1 24 | -7.0% | 20.0% |
资本支出强度DBIRVTY
| Q4 25 | 1.2% | 2.6% | ||
| Q3 25 | 1.3% | 2.6% | ||
| Q2 25 | 1.1% | 2.6% | ||
| Q1 25 | 1.7% | 2.4% | ||
| Q4 24 | 1.2% | 3.4% | ||
| Q3 24 | 1.8% | 3.3% | ||
| Q2 24 | 2.1% | 3.2% | ||
| Q1 24 | 1.7% | 2.7% |
现金转化率DBIRVTY
| Q4 25 | 3.65× | 1.85× | ||
| Q3 25 | 1.98× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | -0.75× | 1.84× | ||
| Q3 24 | 3.01× | 1.57× | ||
| Q2 24 | -25.13× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DBI
| Womens | $280.7M | 37% |
| Athletic Footwear | $188.6M | 25% |
| Wholesale | $89.8M | 12% |
| Canada Retail Segment | $77.3M | 10% |
| Mens | $76.1M | 10% |
| Kids | $24.2M | 3% |
| Commission Income | $10.8M | 1% |
| Directto Consumer | $1.3M | 0% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
